Background: Quercetin is a naturally occurring flavonoid with many biological activities including inhibition of a number of tyrosine kinases. A phase I, dose-escalation trial of quercetin defined the maximum tolerated dose (MTD) as 1700 mg/m
Introduction
Quercetin (3,3',4',5,7-pentahydroxyflavone) is a naturally occurring flavonoid found in all aerial plants [1, 2] . It is a component of the normal diet with the highest concentrations being found in onions, apples and red wine. Quercetin has many biological activities, which render it a potentially useful anti-tumour agent; anti-proliferative effects on a wide range of human cancer cell lines; sensitisation of lung tumour xenografts to cisplatin; inhibition of a range of tyrosine kinases involved in cell signalling [3, 4] ; down regulation of mutant p53 in a breast cancer cell line in vitro [5] ; inhibition of the metabolism of taxol by the cytochrome p450 system [6] . A previous phase I trial with quercetin, co-ordinated in our institution defined the MTD as 1700 mg/m 2 administered by brief i.v. infusion every three weeks [3] . The dose limiting toxicity (DLT) was reversible nephrotoxicity; there was no myelosupression, mucositis, alopecia or diarrhoea. The preceding dose level, 1400 mg/m 2 was the recommended dose for further study.
Clinical trials exploring different schedules of administration of quercetin have been hampered by its extreme water insolubility requiring dissolution in dimethylsulphoxide (DMSO) (150 mg of quercetin is soluble in 1 ml of DMSO). There are concerns about using higher doses of DMSO [7, 8] as it causes dose dependent haemolysis, solubilises some plastics and causes an unpleasant odour for 48 hours after administration. In order to overcome these limitations, a synthetic chemistry programme was undertaken to produce water-soluble derivatives of quercetin. The most promising of these, QC12, (3'-(N-carboxymethyl)carbamoyl-3,4',5,7-tetrahydroxyflavone) (Figure 1 ) was selected for pre-clinical and clinical study. This short report describes the //; vitro and clinical pharmacokinetic properties of QC12.
Patient and methods

In vitro studies
The purity of the original QC12 powder was checked by high performance liquid chromatography (HPLC) and found to be 97% pure with only 3% quercetin. The QC12 was stored as a powder at -20 °C
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Figure I Structure of QC12 (3'-(N-carboxymethyl)carbamoyl-3,4',5.7-tetrahydroxyflavone), quercetin prodrug. The structure is hydrolysed in vivo at the arrowed oxygen to release quercetin and glycine. and was dissolved in water to make up a stock concentration of 20 mg/ml.
Antiproliferative activity of QCI2 was estimated using the colorimctric MTT conversion assay of Mossmann [9] , Human ovarian carcinoma cells (A2780). A2780 cells transfected with BCL-2 (A270 BCL-2) and the acquired cisplatin resistant variant (2780CP) were trypsinised and plated out at a density of 4000-6000 cells per well into a 96 well plate and allowed to rest overnight. The next day the cells were treated with various concentrations of QCI2 ranging from 10 uM to 200 uM. Forty-eight hours later 20 ul of 5 mg/ml MTT were added in each well, incubated for four hours at 37 °C and the formazon crystals formed were dissolved in DMSO. The optical density was recorded at 550nm on a Becton Dickenson Multiscan. The inhibitory concentration 50% (IC 5 o) value was the drug concentration inducing 50% reduction in the optical density.
Clinical study
The eligibility criteria were: malignancy which is refractory to conventional therapy or for which there is no standard treatment; WHO performance status of 0. 1 or 2; age > 18; life expectancy of more than 12 weeks; no systemic anti-cancer therapy within the previous 4 weeks (6 weeks for nitrosoureas or mitomycin C); haemoglobin >IO g/dl. WBC count > 3.0 x IO 9 /I, platelets > 100 x 1O 9 /I, serum bilirubin less than 1.25 upper limit of reference range (ULRR), ALT or AST less than 2.5 ULRR if no demonstrable liver metastases. or less than 5 x ULRR in the presence of liver metastases, serum creatinine less than 1.25 x ULRR; capable of giving informed consent, as approved by the Ethics committee of the Queen Elizabeth Hospital (Birmingham, UK).
Patients received one intravenous treatment and one oral treatment separated by fourteen days The oral QC12 was given at a fixed dose of 400 mg made up fresh in 100 ml of orange juice, the patients having fasted from the previous evening from 11 pm. The intravenous QCI2 was also a fixed dose of 400 mg dissolved in 40 ml of normal saline as a five-minute infusion. This dose was selected on the basis of previous clinical experience with intravenous administration of quercetin dissolved in DMSO and on munne toxicity profile of QC12, which gave an LD|o in excess of 250 mg/kg, by i.v. bolus (data not shown). Toxicity data were graded according to the first NCI-CTC system. Pharmacokinetic data was collected from the patients on these first two treatments. If it was thought on clinical grounds that the patients might be benefiting from the treatment, they continued to have intravenous QC12 every 14 days, up to a maximum of six treatments in total.
Pharmacokinetics
Venous blood samples for pharmacokinetics were drawn at frequent intervals. 0, 5. 10. 15, 30,60 and 120 minutes. The blood was placed into Li-heparin tubes, and was centrifuged immediately. The plasma was separated, frozen in liquid nitrogen and stored at -20 °C before being analysed by reversed phase HPLC.
HPLC determination of QC12 and quercetin in plasma
QCI2 and quercetin levels were estimated using a method developed in our laboratory. Chloroform: propanol (1:1 W.W) mixture was used for extraction of both quercetin and QCI2. This was followed by HPLC determination using Water u-bondpak (CIS) column. The mobile phase was 40% acetonitrile in 0.04% trifluoracetic acid. Detection wavelength was 254 nm and 375 nm.
Pharmacokinetic modelling
The pharmacokinelic data was fitted using non-linear regression to a two-compartment model, which allowed calculation of half-life, clearance, volume of distribution and area under the concentrationtime curves (AUC). 
Results
Stability of QC12
Hydrolysis of QC12 to quercetin at 37 °C proceeded in water with a half-life of 16.9 hours and in blood, 0.39 hours (Figure 2 ).
In vitro activity
Cell survival curves following 48 hours exposure to QC12 are summarised in Figure 3 . The parental ovarian cancer cell line (A2780) had an IC 50 of 59 uM, whereas the BCL-2 transfected variant (A2780-5CL-2) and cisplatin resistant variant (A2780-CP) were relatively resistant to QC12 with IC 50 values of 75 uM and 151 uM, respectively. Flow cytometric analysis suggested that QC12 induces a dose related late S/early G2 cell cycle block (data not shown).
Patients
Six patients were entered into this study, two had colorectal cancer with liver metastases, two had hepatocellular carcinoma, one had pelvic recurrence of leiomyosarcoma and one had thoracic mesothelioma. There were three males and three females and their ages ranged from 29-67 with a median age of 54. All six patients entered into the study completed the first oral and i.v. treatments. One patient had four additional i.v. treatments, two had three further treatments, one had two treatments and two patients had one addi- tional treatment. The patients who did not complete six treatments stopped because of disease progression.
Toxicity
There was no reported toxicity following the oral administration of 400 mg of QC12. For i.v. QC12 there was no myelosupression, emesis, or renal toxicity. Two patients suffered lethargy, one patient had common toxicity criteria (CTC) grade 2 lethargy at treatments 4 and 5 and another patient had grade two lethargy at treatments 2 and 3. However, in both patients the lethargy coincided with disease progression. Two patients had moderate pain in the muscle above the injection site on intravenous infusion; both patients were female and had poor venous access. The pain of injection was overcome by infusing with a fast running drip of normal saline and slowing the infusion time down to 10-15 minutes in both patients.
Pharmacokinetics
Neither QC12 nor quercetin were detected in the serum following oral administration, however up to 3% of the administered QC12 was detected in the urine. Following i.v. administration of QC12 both the pro-drug and the quercetin were detected in the serum.
The pharmacokinetic parameters are summarised in Table 1 and Figure 2 . The data for QC12 fitted a twocompartment model with a mean ti /2 a of 0.31 ± 0.27 hours, mean ti /2 (3 of 0.86 ± 0.78 hours, mean AUC of 44.54 ± 13.0 uMhour, mean Vd of 10.0 ± 6.24 L and mean clearance of 21.31 ± 12.9 I/hour.
Discussion
In order to develop quercetin as a useful therapeutic agent, it is necessary to either find a better vehicle than DMSO or to have a water-soluble pro-drug. This will greatly increase the flexibility of scheduling, improve ease of administration and patient tolerance. The prodrug QC12 has antiproliferative activity in a range of ovarian cancer cell lines. Interestingly, transfection with BCL-2 or selection of a cisplatin resistant variant renders these cells relatively resistant to QC12, implying cross-resistance. QC12 induces a late S/early G2 cell cycle block and parallel studies with quercetin suggest that this toxicity effect is mediated by quercetin released by hydrolysis in vitro (data not shown). QC12 is converted to quercetin much more rapidly in plasma than in water at 37 °C implying that there are plasma enzymes responsible for catalysing hydrolysis of QC12 to quercetin and glycine. Prior to undertaking a formal dose escalation phase I study, it seemed prudent to determine the pharmacokinetics of QC12 in cancer patients. As it was, at least theoretically, possible that the rate constants governing distribution and metabolism of QC12 could be more rapid than the rate of hydrolysis to quercetin, thus negating the utility of the pro-drug. Put simply, there would be no point in commencing phase I studies if the prodrug was excreted intact in the urine without releasing quercetin.
This pharmacokinetic study demonstrates that QC12, like quercetin, is not orally bioavailable [10] . Intravenous infusion of QC12 at a dose of 400 mg is associated with very little toxicity. QC12 undergoes hydrolysis to quercetin to a significant degree. The released quercetin has a distribution half-life of 0.13 ± 0.06 hours and a t| /2 P of 0.59 ± 0.57 hours, which are very similar to the values seen in the earlier phase I and pharmacokinetic study of quercetin [3] . A QC12 dose of 400 mg is approximately equivalent to 175 mg/m 2 of quercetin. As quercetin has linear kinetics it is possible to derive the projected plasma AUC and calculate the relative bioavailability by dividing the quercetin plasma area under data (AUD) following administration of QC12 by the plasma AUD of dose equivalent of i.v. quercetin (175 mg/m 2 ). The ratio gives an estimate of the relative availability of quercetin of 20%-25% of the administered i.v. doseofQC12.
In our previous phase I study we reported evidence of anti-tumour activity of quercetin in three patients (two ovary and one hepatocellular cancer) when administered by brief i.v. infusion. Given its potential for signal transduction inhibition, for sensitising cancer cells to cisplatin and Taxol and inhibiting the metabolism of Taxol, it was deemed essential to develop a water-soluble pro-drug of quercetin in order to provide more flexible schedules of administration. Intravenous QC12 warrants progression to phase I and pharmacokinetic trial as a single agent and in combination with cisplatin and Taxol.
